Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Assets (2018 - 2025)

Historic Return on Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to 0.34%.

  • Crinetics Pharmaceuticals' Return on Assets fell 500.0% to 0.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.34%, marking a year-over-year decrease of 500.0%. This contributed to the annual value of 0.29% for FY2024, which is 1400.0% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Return on Assets is 0.34%, which was down 500.0% from 0.28% recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Return on Assets peaked at 0.23% during Q1 2025, and registered a low of 0.61% during Q2 2023.
  • For the 5-year period, Crinetics Pharmaceuticals' Return on Assets averaged around 0.35%, with its median value being 0.33% (2021).
  • Its Return on Assets has fluctuated over the past 5 years, first crashed by -2600bps in 2023, then surged by 3400bps in 2024.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Return on Assets stood at 0.29% in 2021, then tumbled by -53bps to 0.44% in 2022, then grew by 26bps to 0.33% in 2023, then grew by 23bps to 0.25% in 2024, then plummeted by -36bps to 0.34% in 2025.
  • Its Return on Assets stands at 0.34% for Q3 2025, versus 0.28% for Q2 2025 and 0.23% for Q1 2025.